Literature DB >> 24939539

[Lp-PLA2 and sPLA2: cardiovascular biomarkers].

Hafid Ait-Oufella1, Ziad Mallat2, Alain Tedgui3.   

Abstract

Phospholipases A2 (PLA2) belong to a superfamily of enzymes that catalyze the hydrolysis of glycerophospholipids at the sn-2 position, producing nonesterified fatty acids and lysophospholipids. Many experimental studies have shown that PLA2 are involved in lipid metabolism and immuno-inflammatory response and participate in the development of atherosclerosis. In humans, therapeutic approaches based on the inhibition of PLA2 are currently in development. This review summarizes human studies regarding the prognostic value of two members of the family of PLA2, Lp-PLA2 (lipoprotein-associated PLA2) and sPLA2 (secretory PLA2), in cardiovascular diseases.
© 2014 médecine/sciences – Inserm.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24939539     DOI: 10.1051/medsci/20143005015

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  2 in total

1.  Measuring lipoprotein-associated phospholipase A2 activity in China: Protocol comparison and recalibration.

Authors:  Danchen Wang; Xiuzhi Guo; Li'an Hou; Xinqi Cheng; Tingting You; Honglei Li; Liangyu Xia; Yicong Yin; Songlin Yu; Ling Qiu
Journal:  J Clin Lab Anal       Date:  2018-07-24       Impact factor: 2.352

2.  Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.

Authors:  Juan Zhang; Dong Ling Xu; Xiao Bo Liu; Shao Jie Bi; Tong Zhao; Shu Jian Sui; Xiao Ping Ji; Qing Hua Lu
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.